Crinetics Chief Development Officer Ajay Madan resigns effective April 1, 2022

Crinetics Pharmaceuticals, Inc.

Ajay Madan, Ph.D., resigns as Chief Development Officer, effective April 1, 2022.
Company expects to enter a six-month consulting agreement with Madan for transition support.
Consulting retainer of approximately $37,346 per month.
No replacement named; company will search for successor.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ajay Madan

Chief Development Officer

CRNX · Crinetics Pharmaceuticals, Inc.

Effective: 2022-04-01
Filed: March 25, 2022, 7:59 PM ET

On March 21, 2022, Ajay Madan, Ph.D., provided notice to the Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Development Officer of the Company, to be effective April 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ajay Madan resigned as Chief Development Officer at Crinetics Pharmaceuticals, Inc..

Action: resigned
Role: Chief Development Officer

Exact text from the filing

On March 21, 2022, Ajay Madan, Ph.D., provided notice to the Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Development Officer of the Company, to be effective April 1, 2022.

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-004687

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.